CNS Pharmaceuticals to Participate in A.G.P.'s Virtual Healthcare Symposium

Rhea-AI Summary

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced its participation in A.G.P.'s Virtual Healthcare Symposium on November 19, 2020. The event will feature 1-on-1 virtual meetings for investors to connect with company management. CNS is focused on developing treatments for brain and central nervous system cancers, with its lead candidate, Berubicin, targeting glioblastoma multiforme. CNS holds a worldwide exclusive license for Berubicin, which showed a 44% disease control rate in prior trials. A Phase 2 trial for Berubicin is expected to start by the end of 2020.

HOUSTON, Nov. 18, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that members of management will participate in A.G.P.'s Virtual Healthcare Symposium on Thursday, November 19^th, 2020.

The event will consist of 1-on-1 virtual investor meetings. Investors attending the conference virtually who are interested in meeting with Company management should contact their A.G.P. representative.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of Feb. 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation.

For more information, please visit www.CNSPharma.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-participate-in-agps-virtual-healthcare-symposium-301175686.html

SOURCE CNS Pharmaceuticals, Inc.

FAQ

What is CNS Pharmaceuticals' participation in A.G.P.'s Virtual Healthcare Symposium?

CNS Pharmaceuticals will participate in A.G.P.'s Virtual Healthcare Symposium on November 19, 2020, offering 1-on-1 virtual meetings for investors.

What is the significance of Berubicin for CNS Pharmaceuticals?

Berubicin is CNS Pharmaceuticals' lead drug candidate aimed at treating glioblastoma multiforme, an aggressive brain cancer, and has shown a 44% disease control rate in prior studies.

When does CNS Pharmaceuticals plan to start a Phase 2 trial for Berubicin?

CNS Pharmaceuticals expects to commence a Phase 2 clinical trial for Berubicin by the end of 2020.

What other drug candidate is CNS Pharmaceuticals developing?

In addition to Berubicin, CNS Pharmaceuticals is developing WP1244, a DNA binding agent that is 500 times more potent than daunorubicin in preclinical studies.

What was the outcome of Berubicin's Phase 1 clinical trial?

The Phase 1 trial of Berubicin showed a 44% response rate, with one patient achieving a durable complete response and remaining cancer-free as of February 2020.